Le Lézard
Classified in: Health, Science and technology
Subjects: Product/Service, Annual Meeting

Strand Therapeutics Announces First Patient Dosed with Programmable mRNA Therapy STX-001 in Phase 1 Trial for Solid Tumors


Strand Therapeutics, the world's first programmable mRNA company developing curative therapies for cancer, autoimmune diseases, and beyond, today announced the first patient has been dosed in their Phase 1, first-in-human trial of STX-001, an investigational multi-mechanistic, synthetic self-replicating mRNA technology that expresses an IL-12 cytokine for an extended duration, directly into the tumor microenvironment.

"STX-001 represents the first programmable mRNA therapy in oncology to enter the clinic for the treatment of solid tumors," said Jake Becraft, Ph.D., CEO & Co-Founder, Strand Therapeutics. "We are proud of this remarkable achievement for patients and for Strand Therapeutics to be able to take STX-001 from the lab to the clinic to evaluate the potential of this novel treatment approach for cancer patients with solid tumors."

STX-001 shows promise as a new approach to improve the efficacy of immunotherapy for solid tumors. In animal models, STX-001's self-replicating mRNA technology induced immunogenic cancer cell death and promoted recruitment of T cells and NK cells to the tumor microenvironment, as well as their activation, by directly expressing an IL-12 payload from the synthetic mRNA directly from the tumor cells themselves.

"Significant progress has been made to date with current immunotherapies to address unmet patient needs in various solid tumors, but more work needs to be done to induce durable clinical responses in patients with minimal toxicities," said Tasuku Kitada, Ph.D., Co-Founder, President, and Head of R&D, Strand Therapeutics. "We are eager to advance our work with STX-001 and continue to pioneer the development of programmable mRNA therapies to provide targeted and precise immune activation to the tumor microenvironment."

Strand at ASCO

The first patient dosed with STX-001 comes days before the start of the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31 ? June 4 in Chicago. Strand will present a poster on the Phase 1 trial design. The Phase 1 trial is an open-label, multi-center first-in-human dose-escalation trial, evaluating the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of STX-001 alone, or in combination with pembrolizumab in patients with treatment refractory advanced solid tumors.

Details of the presentation are as follows:

Presentation Title: A phase I trial of intratumoral STX-001: A novel self-replicating mRNA expressing IL-12 alone or with pembrolizumab in advanced solid tumors.

Session Type: Poster Session

Session Title: Developmental Therapeutics -- Immunotherapy

Track: Developmental Therapeutics ? Immunotherapy

Sub-Track: New Targets and Technologies (IO)

Session Date and Time: Saturday, June 1, 9:00AM ? 12:00PM CDT

Location: McCormick Place, Chicago, Illinois, Hall A

Poster Board Number: 161b

Permanent Abstract Number: TPS2696

Additional meeting information is available on the ASCO website.

About Strand Therapeutics

Strand Therapeutics is a next-generation biotechnology company committed to transforming the lives of patients by developing first-in-class programmable mRNA therapeutics. Founded by leaders in mRNA-based synthetic biology at MIT, Strand is creating the first platform for programmable, long-acting mRNA therapeutics that are bioengineered to enable precise control of the location, timing, intensity, and duration of therapeutic activity. Strand's mission is to develop improved treatment options for cancer and other life-threatening diseases. The company is headquartered in Boston, MA. For more information, visit www.strandtx.com. Follow us @StrandTx.


These press releases may also interest you

at 12:45
SummaryProducts: Dianeal PD4 2.5% Dextrose peritoneal dialysis solution (3,000 mL and 5,000 mL); Physioneal 40 2.27% Glucose peritoneal dialysis solution (2,500 mL)Issue: Health products ? Product safetyWhat to do: Immediately check your stock to see...

at 10:45
Pomerantz LLP announces that a class action lawsuit has been filed against Altimmune, Inc. ("Altimmune" or the "Company") and certain officers. The class action, filed in the United States District Court for the District of Maryland, Southern...

at 10:30
IASO biotechnology ("IASO Bio"), a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies and antibody products, presented clinical data on the use of Equecabtagene Autoleucel (Eque-cel),...

at 10:05
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today statistically significant and clinically meaningful results from its Phase III STARGLO study of Columvi® (glofitamab-gxbm) in combination with gemcitabine and...

at 09:00
The Minister of Labour and Seniors, Seamus O'Regan Jr., and the Minister of Mental Health and Addictions and Associate Minister of Health, Ya'ara Saks, issued the following statement on World Elder Abuse Awareness Day: "Elder abuse is a crime that...

at 09:00
From June 15 to July 15, the premium health supplement brand, Vimergy, will be featured in the Medical Medium created smoothie, available at all Erewhon locations. Created by Medical Medium Anthony William, the smoothie will feature Vimergy Barley...



News published on and distributed by: